{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:31:41Z","timestamp":1790980301633,"version":"4.1.0"},"reference-count":60,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,10,20]],"date-time":"2009-10-20T00:00:00Z","timestamp":1255996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p><jats:bold>Background and purpose:\u2002<\/jats:bold>Nitric oxide (NO) controls numerous physiological processes by activation of its receptor, guanylyl cyclase (sGC), leading to the accumulation of 3\u2032\u20105\u2032 cyclic guanosine monophosphate (cGMP). Ca<jats:sup>2+<\/jats:sup>\u2010calmodulin (CaM) regulates both NO synthesis by NO synthase and cGMP hydrolysis by phosphodiesterase\u20101. We report that, unexpectedly, the CaM antagonists, calmidazolium, phenoxybenzamine and trifluoperazine, also inhibited cGMP accumulation in cerebellar cells evoked by an exogenous NO donor, with IC<jats:sub>50<\/jats:sub>values of 11, 80 and 180\u2003\u00b5M respectively. Here we sought to elucidate the underlying mechanism(s).<\/jats:p><jats:p><jats:bold>Experimental approach:\u2002<\/jats:bold>We used cerebellar cell suspensions to determine the influence of CaM antagonists on all steps of the NO\u2010cGMP pathway. Homogenized tissue and purified enzyme were used to test effects of calmidazolium on sGC activity.<\/jats:p><jats:p><jats:bold>Key results:\u2002<\/jats:bold>Inhibition of cGMP accumulation in the cells did not depend on changes in intracellular Ca<jats:sup>2+<\/jats:sup>concentration. Degradation of cGMP and inactivation of NO were both inhibited by the CaM antagonists, ruling out increased loss of cGMP or NO as explanations. Instead, calmidazolium directly inhibited purified sGC (IC<jats:sub>50<\/jats:sub>= 10\u2003\u00b5M). The inhibition was not in competition with NO, nor did it arise from displacement of the haem moiety from sGC. Calmidazolium decreased enzyme<jats:italic>V<\/jats:italic><jats:sub>max<\/jats:sub>and<jats:italic>K<\/jats:italic><jats:sub>m<\/jats:sub>, indicating that it acts in an uncompetitive manner.<\/jats:p><jats:p><jats:bold>Conclusions and implications:\u2002<\/jats:bold>The disruption of every stage of NO signal transduction by common CaM antagonists, unrelated to CaM antagonism, cautions against their utility as pharmacological tools. More positively, the compounds exemplify a novel class of sGC inhibitors that, with improved selectivity, may be therapeutically valuable.<\/jats:p>","DOI":"10.1111\/j.1476-5381.2009.00416.x","type":"journal-article","created":{"date-parts":[[2009,10,20]],"date-time":"2009-10-20T14:31:10Z","timestamp":1256049070000},"page":"1454-1464","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inhibition of nitric oxide\u2010activated guanylyl cyclase by calmodulin antagonists"],"prefix":"10.1111","volume":"158","author":[{"given":"LR","family":"James","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CH","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Garthwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TC","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707746"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.59.1.54"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M006677200"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704687"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.6.2928"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1155"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/10715769900301161"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.2.682"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122225199"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(70)90747-3"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.2.599"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2810291"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(88)90036-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(97)01087-0"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.76.060305.150444"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)61079-0"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2038"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2008.06285.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0026-895X(25)10233-2","article-title":"Potent and selective inhibition of nitric oxide\u2010sensitive guanylyl cyclase by 1H\u2010[1,2,4]oxadiazolo[4,3\u2010a]quinoxalin\u20101\u2010one","volume":"48","author":"Garthwaite J","year":"1995","journal-title":"Mol Pharmacol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2070541"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.2001.00855.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.64.6.1349"},{"key":"e_1_2_8_24_1","first-page":"G900","article-title":"Dual regulation of cGMP formation by calcium in pancreatic acinar cells","volume":"268","author":"Gukovskaya AS","year":"1995","journal-title":"Am J Physiol"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20082419"},{"key":"e_1_2_8_26_1","first-page":"367","article-title":"Antioxidant effect of calmodulin antagonists in rat brain homogenate","volume":"76","author":"Hara S","year":"1992","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(00)00349-X"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.63.3.624"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/35058528"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1999.8844"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1999.79.3.661"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi0110894"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj20020933"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20041431"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(00)00140-6"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4226.bloodjournal84124226"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00557a025"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0022-3565(25)20898-9","article-title":"Selective blockade of endothelium\u2010dependent and glyceryl trinitrate\u2010induced relaxation by hemoglobin and by methylene blue in the rabbit aorta","volume":"232","author":"Martin W","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20275"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(90)80848-D"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1992.tb10090.x"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/014107689909200402"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0031-6997(25)06663-3","article-title":"Nitric oxide: physiology, pathophysiology, and pharmacology","volume":"43","author":"Moncada S","year":"1991","journal-title":"Pharmacol Rev"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199300221-00003"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.43.100901.140226"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0968-0004(90)90177-D"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/333664a0"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi990154v"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20040097"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1990.tb14151.x"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707687"},{"key":"e_1_2_8_52_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-895X(25)09113-8","article-title":"Characterization of 1H\u2010[1,2,4]oxadiazolo[4,3\u2010a]quinoxalin\u20101\u2010one as a heme\u2010site inhibitor of nitric oxide\u2010sensitive guanylyl cyclase","volume":"50","author":"Schrammel A","year":"1996","journal-title":"Mol Pharmacol"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2604-06.2006"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1089"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(92)90413-2"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/35065611"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2728(99)00016-X"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd960"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1998.78.1.99"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1987.tb11073.x"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(96)00189-6"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2009.00416.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2009.00416.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T21:11:01Z","timestamp":1739394661000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2009.00416.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,28]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1476-5381.2009.00416.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00416.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,28]]},"assertion":[{"value":"2009-10-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}